First-in-man phase I, open-label, dose-escalating clinical and pharmacokinetic study of the novel antimicrotubulin agent PM060184 administered over 10 minutes on days 1, 8, and 15 every four weeks to patients with advanced malignant solid tumours

被引：0
|
作者：
Delord, J. P. [1 ]
Elez, E. [2 ]
Gomez Roca, C. [1 ]
Coronado, C. [3 ]
Lignon, N. [1 ]
Martinez de Arenzana, L. [2 ]
Fudio, S. [3 ]
De Miguel Lillo, B. [3 ]
Matos Pita, A. Soto [3 ]
Tabernero, J. [2 ]
机构：
[1] Inst Claudius Regaud, Toulouse, France
[2] Hosp Valle De Hebron, Barcelona, Spain
[3] PharmaMar, Clin Oncol, Madrid, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
889
引用
收藏
页码：S188 / S188
页数：1
相关论文
共 15 条
  • [1] Phase I, open-label, dose-escalating clinical and pharmacokinetic study of the novel antimicrotubulin agent PM060184 administered over 10 Minutes on day 1 and 8 every three weeks to patients with advanced malignant solid tumors
    Hidalgo, M.
    Tolcher, A.
    Cubillo, A.
    Rasco, D.
    Boni, V.
    Patnaik, A.
    Calvo, E.
    Amaya, A.
    Matos Pita, A. Soto
    Papadopoulos, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S188 - S188
  • [2] Phase I, open-label, dose-escalating clinical and pharmacokinetic study of the novel antimicrotubulin agent PM060184 administered over 10 minutes on days 1-3 and 15-17 every 28 days to patients with advanced malignant solid tumors
    Hidalgo, M.
    Boni, V.
    Tolcher, A.
    Smith, L.
    Cubillo, A.
    Rasco, D.
    Calvo, E.
    Amaya, A.
    Ordonez, E.
    Patnaik, A.
    Cerda, S.
    Coronado, C.
    Fudio, S.
    Miguel-Lillo, B.
    Prados, R.
    Ortega, O.
    Soto-Matos, A.
    Papadopoulos, K. P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S74 - S74
  • [3] Phase I, open-label, dose-escalating clinical and pharmacokinetic study of PM00104 administered weekly resting every fourth week, intravenously, over 1 hour to patients with advanced malignant solid tumors or lymphoma
    Plummer, Ruth
    Coronado, C.
    Massard, Christophe
    Calvert, A. H.
    Margetts, J.
    Bahleda, Rastilav
    Prados, R.
    Kahatt, C.
    Soria, Jean-Charles
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [4] A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours
    Scheulen, M.
    Mross, K.
    Richly, H.
    Nokay, B.
    Frost, A.
    Scharr, D.
    Lee, K. H.
    Saunders, O.
    Hilbert, J.
    Fietz, O.
    EJC SUPPLEMENTS, 2010, 8 (07): : 158 - 159
  • [5] A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours
    Dumez, H.
    Awada, A.
    Piccart, M.
    Assadourian, S.
    Semiond, D.
    Guetens, G.
    de Boeck, G.
    Maes, R. A. A.
    de Bruijn, E. A.
    van Oosterom, A.
    ANNALS OF ONCOLOGY, 2006, 17 (07) : 1158 - 1165
  • [6] A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors.
    Scheulen, M. E.
    Mross, K. B.
    Richly, H.
    Nokay, B.
    Frost, A.
    Scharr, D.
    Lee, K.
    Saunders, O.
    Hilbert, J.
    Fietz, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
    H. Murakami
    T. Kurata
    Y. Onozawa
    J. Watanabe
    A. Ono
    T. Takahashi
    N. Yamamoto
    Y. Fujisaka
    H. Kiyota
    H. Hayashi
    K. Tanaka
    K. Nakagawa
    S. Kuroda
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 623 - 630
  • [8] An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
    Murakami, H.
    Kurata, T.
    Onozawa, Y.
    Watanabe, J.
    Ono, A.
    Takahashi, T.
    Yamamoto, N.
    Fujisaka, Y.
    Kiyota, H.
    Hayashi, H.
    Tanaka, K.
    Nakagawa, K.
    Kuroda, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 623 - 630
  • [9] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors.
    Garrido-Laguna, Ignacio
    Dillon, Patrick Michael
    Anthony, Stephen Patrick
    Janat-Amsbury, Margit
    Ashenbramer, Nissa
    Warner, Steven L.
    Mouritsen, Lars
    Wade, Mark L.
    Whatcott, Clifford
    Bearss, David
    Fu, Siqing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors
    De Jonge, M.
    Steeghs, N.
    Verweij, J.
    Nortier, J. W. R.
    Eskens, F.
    Ouwerkerk, J.
    Van Noort, C.
    Carpinelli, R.
    Spinelli, R.
    Bologna, F.
    Gelderblom, H.
    EJC SUPPLEMENTS, 2006, 4 (12): : 12 - 12
12